Scarica l'app Stockscreener
1.90
0.00%
0.00
Dopo l'orario di chiusura:
1.88
-0.02
-1.05%
Precedente Chiudi:
$1.90
Aprire:
$1.93
Volume 24 ore:
12,749
Relative Volume:
0.16
Capitalizzazione di mercato:
$6.22M
Reddito:
$960.60K
Utile/perdita netta:
$-7.10M
Rapporto P/E:
-0.2513
EPS:
-7.56
Flusso di cassa netto:
$-8.00M
1 W Prestazione:
-3.55%
1M Prestazione:
-5.00%
6M Prestazione:
-46.33%
1 anno Prestazione:
-67.33%
Intervallo 1D:
$1.87
$1.94
Intervallo di 1 settimana:
$1.87
$2.00
Portata 52W:
$1.68
$14.83
Soligenix Inc Stock (SNGX) Company Profile
Nome
Soligenix Inc
Settore
Industria
Telefono
609-538-8200
Indirizzo
29 EMMONS DRIVE, PRINCETON
Confronta SNGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.90 | 6.22M | 960.60K | -7.10M | -8.00M | -7.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.38 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.99 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
561.75 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.40 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
225.77 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-07-28 | Downgrade | Dawson James | Buy → Neutral |
| 2018-01-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | Reiterato | Maxim Group | Buy |
| 2017-07-17 | Iniziato | H.C. Wainwright | Buy |
Soligenix Inc Borsa (SNGX) Ultime notizie
SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte™ in CTCL… - MSN
Soligenix Reports Q1 2025 Financial Results and Milestones - TipRanks
SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte in CTCL - Research Tree
Contrasting Schrödinger (NASDAQ:SDGR) and Soligenix (NASDAQ:SNGX) - Defense World
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results - Nasdaq
Soligenix Announces Recent Accomplishments And First Quarter 202 - GuruFocus
Soligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast Episode - The Globe and Mail
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc. - The Manila Times
Geode Capital Management LLC Has $71,000 Stake in Soligenix, Inc. (NASDAQ:SNGX) - Defense World
Soligenix (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer - Barchart.com
Soligenix (SNGX) Projected to Post Quarterly Earnings on Friday - Defense World
Soligenix (NASDAQ: SNGX) Moves Forward To Strengthen The Case For HyBryte(TM) - Barchart.com
Soligenix (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM) - The Globe and Mail
U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Soligenix reports positive results in skin cancer treatment trial By Investing.com - Investing.com India
Fireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc. - Yahoo Finance
Soligenix reports positive results in skin cancer treatment trial - Investing.com Australia
Solgenix shares rise on positive skin cancer treatment results By Investing.com - Investing.com Canada
Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding - The Globe and Mail
EQS-News: Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding - markets.businessinsider.com
Soligenix (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat - Barchart.com
Soligenix (NASDAQ: SNGX) Announces Positive Data, Continued Advancement of HyBryte(TM) - The Globe and Mail
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ f - GuruFocus
SNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses… - MSN
Soligenix Announces Positive Data For Extended HyBryte In Early-stage Cutaneous T-cell Lymphoma - Nasdaq
Soligenix (SNGX) Reports Promising Interim Results for HyBryte i - GuruFocus
Positive Outcome in 75% of CTCL Patients Treated with HyBrytetm for 18 Weeks - Lelezard
Soligenix IncPositive Outcome In 75% Of Ctcl Patients Treated With Hybryte For 18 Weeks - marketscreener.com
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks - Finansavisen
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks (PR Newswire) - Aktiellt
SNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses - Smartkarma
Behcet's Disease Market to Show Remarkable Growth Trends from - openPR.com
Behcet’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Soligenix, Chugai Pharma, UMC Utrecht, Ganzhou Hemay Pharma, Amgen - The Globe and Mail
Soligenix (NASDAQ: SNGX) Spotlighted In Zacks Small-Cap Research Report, Earns $35 Valuation - Barchart.com
Soligenix (NASDAQ: SNGX) Spotlighted in Zacks Small-Cap Research Report, Earns $35 Valuation - The Globe and Mail
SNGX stock touches 52-week low at $1.74 amid market challenges - Investing.com Canada
SNGX stock touches 52-week low at $1.74 amid market challenges By Investing.com - Investing.com South Africa
Soligenix (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment - Barchart.com
Zacks Small Cap Decreases Earnings Estimates for Soligenix - The AM Reporter
Zacks Maintains $35.00 Price Per Share Valuation for Soligenix (NASDAQ: SNGX) Amid Promising Vaccine and CTCL Therapy Progress - Barchart.com
Q1 Earnings Forecast for Soligenix Issued By Zacks Small Cap - Defense World
SNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19… - Yahoo Finance
IBN Initiates Coverage of Soligenix Inc. - GlobeNewswire
SNGX: Preclinical Data Shows CiVax Booster Induces Broad Protection Against COVID-19 - Smartkarma
CiVax booster shows broad COVID-19 variant protection By Investing.com - Investing.com South Africa
Soligenix Inc Azioni (SNGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):